Immunogenicity and safety of the human papillomavirus vaccine in patients with autoimmune diseases: A systematic review

Vaccine

Volumn 33, Issue 30, 2015, Pages 3444-3449

  Pellegrino, Paolo ^a   Radice, Sonia ^a   Clementi, Emilio ^a,b  

^a UNIVERSITY OF MILAN   (Italy)

^b SCIENTIFIC INSTITUTE   (Italy)

Author keywords

Autoimmune diseases; Cost effectiveness; HPV vaccines; Safety

Indexed keywords

MYCOPHENOLATE MOFETIL; PREDNISOLONE; RITUXIMAB; WART VIRUS VACCINE;

ANTIBODY RESPONSE; AUTOIMMUNE DISEASE; COST EFFECTIVENESS ANALYSIS; CROHN DISEASE; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; HUMORAL IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; JUVENILE RHEUMATOID ARTHRITIS; LOW BACK PAIN; METHODOLOGY; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; UVEITIS; VACCINATION; COST BENEFIT ANALYSIS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ECONOMICS; IMMUNOLOGY;

AUTOIMMUNE DISEASES; COST-BENEFIT ANALYSIS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; PAPILLOMAVIRUS VACCINES;

EID: 84931569118     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.05.041     Document Type: Review

References (58)

1. Harper D.M., Vierthaler S.L., Santee J.A. Review of gardasil. J Vaccines Vaccin 2010, 1.
2. Harper D.M., Williams K.B. Prophylactic HPV vaccines: current knowledge of impact on gynecologic premalignancies. Discov Med 2010, 10:7-17.
3. Harper D.M., Vierthaler S.L. Next generation cancer protection: the bivalent HPV vaccine for females. ISRN Obstet Gynecol 2011, 2011:457204.
4. Bosch F.X., de Sanjose S. Chapter 1: human papillomavirus and cervical cancer-burden and assessment of causality. J Natl Cancer Inst Monogr 2003, 3-13.
5. Harper D.M. HPV vaccine against HPV infection and disease in males. N Engl J Med 2011, 364:2164-2165. 2164; author reply.
6. Kim K.S., Park S.A., Ko K.N., Yi S., Cho Y.J. Current status of human papillomavirus vaccines. Clin Exp Vaccine Res 2014, 3:168-175.
7. Ma B., Roden R., Wu T.C. Current status of human papillomavirus vaccines. J Formos Med Assoc 2010, 109:481-483.
8. Garland S.M., Smith J.S. Human papillomavirus vaccines: current status and future prospects. Drugs 2010, 70:1079-1098.
9. Joura E.A., Giuliano A.R., Iversen O.E., Bouchard C., Mao C., Mehlsen J., et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med 2015, 372:711-723.
10. Dreyer L., Faurschou M., Mogensen M., Jacobsen S. High incidence of potentially virus-induced malignancies in systemic lupus erythematosus: a long-term followup study in a Danish cohort. Arthritis Rheum 2011, 63:3032-3037.
11. Zard E., Arnaud L., Mathian A., Chakhtoura Z., Hie M., Touraine P., et al. Increased risk of high grade cervical squamous intraepithelial lesions in systemic lupus erythematosus: a meta-analysis of the literature. Autoimmun Rev 2014, 13:730-735.
12. Rojo-Contreras W., Olivas-Flores E.M., Gamez-Nava J.I., Montoya-Fuentes H., Trujillo-Hernandez B., Trujillo X., et al. Cervical human papillomavirus infection in Mexican women with systemic lupus erythematosus or rheumatoid arthritis. Lupus 2012, 21:365-372.
13. Feldman C.H., Kim S.C. Should we target patients with autoimmune diseases for human papillomavirus vaccine uptake?. Expert Rev Vaccines 2014, 13:931-934.
14. Santana I.U., Gomes Ado N., Lyrio L.D., Rios Grassi M.F., Santiago M.B. Systemic lupus erythematosus, human papillomavirus infection, cervical pre-malignant and malignant lesions: a systematic review. Clin Rheumatol 2011, 30:665-672.
15. Cibere J., Sibley J., Haga M. Systemic lupus erythematosus and the risk of malignancy. Lupus 2001, 10:394-400.
16. Murdaca G., Orsi A., Spano F., Puppo F., Durando P., Icardi G., et al. Influenza and pneumococcal vaccinations of patients with systemic lupus erythematosus: current views upon safety and immunogenicity. Autoimmun Rev 2014, 13:75-84.
17. Conti F., Rezai S., Valesini G. Vaccination and autoimmune rheumatic diseases. Autoimmun Rev 2008, 8:124-128.
18. Bhatia J., Bratcher J., Korelitz B., Vakher K., Mannor S., Shevchuk M., et al. Abnormalities of uterine cervix in women with inflammatory bowel disease. World J Gastroenterol 2006, 12:6167-6171.
19. Kane S., Khatibi B., Reddy D. Higher incidence of abnormal Pap smears in women with inflammatory bowel disease. Am J Gastroenterol 2008, 103:631-636.
20. Lees C.W., Critchley J., Chee N., Beez T., Gailer R.E., Williams A.R., et al. Lack of association between cervical dysplasia and IBD: a large case-control study. Inflamm Bowel Dis 2009, 15:1621-1629.
21. Kim S.C., Glynn R.J., Giovannucci E., Hernandez-Diaz S., Liu J., Feldman S., et al. Risk of high-grade cervical dysplasia and cervical cancer in women with systemic inflammatory diseases: a population-based cohort study. Ann Rheum Dis 2014, [Epub ahead of print]. 10.1136/annrheumdis-2013-204993.
22. Horneff G. Paediatric rheumatic disease: biologic therapy and risk of infection in children with JIA. Nat Rev Rheumatol 2012, 8:504-505.
23. Beukelman T., Xie F., Chen L., Baddley J.W., Delzell E., Grijalva C.G., et al. Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum 2012, 64:2773-2780.
24. Garland S.M., Hernandez-Avila M., Wheeler C.M., Perez G., Harper D.M., Leodolter S., et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007, 356:1928-1943.
25. Lu B., Kumar A., Castellsague X., Giuliano A.R. Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review & meta-analysis. BMC Infect Dis 2011, 11:13.
26. Szarewski A., Poppe W.A., Skinner S.R., Wheeler C.M., Paavonen J., Naud P., et al. Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16/18. Int J Cancer 2012, 131:106-116.
27. GlaxoSmithKline Vaccine HPVSG, Romanowski B., de Borba P.C., Naud P.S., Roteli-Martins C.M., De Carvalho N.S., et al. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet 2009, 374:1975-1985.
28. Pellegrino P., Carnovale C., Pozzi M., Antoniazzi S., Perrone V., Salvati D., et al. On the relationship between human papilloma virus vaccine and autoimmune diseases. Autoimmun Rev 2014, 13:736-741.
29. Pellegrino P., Carnovale C., Perrone V., Salvati D., Gentili M., Antoniazzi S., et al. Human papillomavirus vaccine in patients with systemic lupus erythematosus. Epidemiology 2014, 25:155-156.
30. Pellegrino P., Carnovale C., Perrone V., Antoniazzi S., Pozzi M., Clementi E., et al. No evidence of a link between multiple sclerosis and the vaccine against the human papillomavirus. Eur J Epidemiol 2013, 28:705-707.
31. Pellegrino P., Carnovale C., Perrone V., Salvati D., Gentili M., Brusadelli T., et al. On the association between human papillomavirus vaccine and primary ovarian failure. Am J Reprod Immunol 2014, 71:293-294.
32. Pellegrino P., Carnovale C., Perrone V., Antoniazzi S., Pozzi M., Clementi E., et al. Can HPV immunisation cause ADEM? Two case reports and literature review. Mult Scler 2014, 20:762-763.
33. Mok C.C., Ho L.Y., Fong L.S., To C.H. Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case-control study. Ann Rheum Dis 2013, 72:659-664.
34. Soybilgic A., Onel K.B., Utset T., Alexander K., Wagner-Weiner L. Safety and immunogenicity of the quadrivalent HPV vaccine in female Systemic Lupus Erythematosus patients aged 12 to 26 years. Pediatr Rheumatol Online J 2013, 11:29.
35. Nazi I., Kelton J.G., Larche M., Snider D.P., Heddle N.M., Crowther M.A., et al. The effect of rituximab on vaccine responses in patients with immune thrombocytopenia. Blood 2013, 122:1946-1953.
36. Pellegrino P., Carnovale C., Perrone V., Pozzi M., Antoniazzi S., Radice S., et al. Efficacy of vaccination against influenza in patients with multiple sclerosis: the role of concomitant therapies. Vaccine 2014, 32:4730-4735.
37. Heijstek M.W., Scherpenisse M., Groot N., Wulffraat N.M., Van Der Klis F.R. Immunogenicity of the bivalent human papillomavirus vaccine in adolescents with juvenile systemic lupus erythematosus or juvenile dermatomyositis. J Rheumatol 2013, 40:1626-1627.
38. Jacobson D.L., Bousvaros A., Ashworth L., Carey R., Shrier L.A., Burchett S.K., et al. Immunogenicity and tolerability to human papillomavirus-like particle vaccine in girls and young women with inflammatory bowel disease. Inflamm Bowel Dis 2013, 19:1441-1449.
39. Esposito S., Corona F., Barzon L., Cuoco F., Squarzon L., Marcati G., et al. Immunogenicity, safety and tolerability of a bivalent human papillomavirus vaccine in adolescents with juvenile idiopathic arthritis. Expert Rev Vaccines 2014, 1-7.
40. Heijstek M.W., Scherpenisse M., Groot N., Tacke C., Schepp R.M., Buisman A.M., et al. Immunogenicity and safety of the bivalent HPV vaccine in female patients with juvenile idiopathic arthritis: a prospective controlled observational cohort study. Ann Rheum Dis 2014, 73:1500-1507.
41. Akioka S. Bivalent HPV vaccine safety depending on subtypes of juvenile idiopathic arthritis. Ann Rheum Dis 2014, [Epub 2014 Aug 27]. 10.1136/annrheumdis-2014-206426.
42. Doran M.F., Crowson C.S., Pond G.R., O'Fallon W.M., Gabriel S.E. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002, 46:2287-2293.
43. Gatto M., Agmon-Levin N., Soriano A., Manna R., Maoz-Segal R., Kivity S., et al. Human papillomavirus vaccine and systemic lupus erythematosus. Clin Rheumatol 2013, 32:1301-1307.
44. Moscandrew M., Mahadevan U., Kane S. General health maintenance in IBD. Inflamm Bowel Dis 2009, 15:1399-1409.
45. Fields S.W., Baiocco P.J., Korelitz B.I. Influenza vaccinations: should they really be encouraged for IBD patients being treated with immunosuppressives?. Inflamm Bowel Dis 2009, 15:649-651. author reply 651-2.
46. Pellegrino P., Perrone V., Pozzi M., Carnovale C., Perrotta C., Clementi E., et al. The epidemiological profile of ASIA syndrome after HPV vaccination: an evaluation based on the Vaccine Adverse Event Reporting Systems. Immunol Res 2014, 10.1007/s12026-014-8567-3.
47. Karussis D., Petrou P. The spectrum of post-vaccination inflammatory CNS demyelinating syndromes. Autoimmun Rev 2014, 13:215-224.
48. Agmon-Levin N., Paz Z., Israeli E., Shoenfeld Y. Vaccines and autoimmunity. Nat Rev Rheumatol 2009, 5:648-652.
49. Agmon-Levin N., Arango M.T., Kivity S., Katzav A., Gilburd B., Blank M., et al. Immunization with hepatitis B vaccine accelerates SLE-like disease in a murine model. J Autoimmun 2014, [Epub 2014 Jul 16]. 10.1016/j.jaut.2014.06.006.
50. Pellegrino P., Falvella F.S., Perrone V., Carnovale C., Brusadelli T., Pozzi M., et al. The first steps towards the era of personalised vaccinology: predicting adverse reactions. Pharmacogenomics J 2014, [Epub 2014 Oct 7]. 10.1038/tpj.2014.57.
51. Skinner S.R., Szarewski A., Romanowski B., Garland S.M., Lazcano-Ponce E., Salmeron J., et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. Lancet 2014, [Epub 2014 Sep 1]. 10.1016/S0140-6736(14)60920-X.
52. Castle P.E., Schmeler K.M. HPV vaccination: for women of all ages?. Lancet 2014, [Epub 2014 Sep 1]. 10.1016/S0140-6736(14)61230-7.
53. Stoof S.P., Heijstek M.W., Sijssens K.M., van der Klis F., Sanders E.A., Teunis P.F., et al. Kinetics of the long-term antibody response after meningococcal C vaccination in patients with juvenile idiopathic arthritis: a retrospective cohort study. Ann Rheum Dis 2014, 73:728-734.
54. Veldhuijzen N.J., Braunstein S.L., Vyankandondera J., Ingabire C., Ntirushwa J., Kestelyn E., et al. The epidemiology of human papillomavirus infection in HIV-positive and HIV-negative high-risk women in Kigali. Rwanda. BMC Infect Dis 2011, 11:333.
55. Camargo M., Soto-De Leon S.C., Munoz M., Sanchez R., Pena-Herrera D., Pineda-Pena A.C., et al. Human papillomavirus detection in women with and without human immunodeficiency virus infection in Colombia. BMC Cancer 2014, 14:451.
56. Carter J.R., Ding Z., Rose B.R. HPV infection and cervical disease: a review. Aust N Z J Obstet Gynaecol 2011, 51:103-108.
57. Toft L., Tolstrup M., Storgaard M., Ostergaard L., Sogaard O.S. Vaccination against oncogenic human papillomavirus infection in HIV-infected populations: review of current status and future perspectives. Sex Health 2014, 11:511-523.
58. Kumar D., Unger E.R., Panicker G., Medvedev P., Wilson L., Humar A. Immunogenicity of quadrivalent human papillomavirus vaccine in organ transplant recipients. Am J Transplant 2013, 13:2411-2417.